Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead Sciences has received marketing authorization from the European Commission for Harvoni (ledipasvir 90mg/sofosbuvir 400mg), the first once-daily single tablet regimen to treat the majority of chronic hepatitis C genotype 1 and 4 infection in adults.
Subscribe to our email newsletter
Harvoni is a combination of the NS5A inhibitor ledipasvir (LDV) and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) and is indicated to treat adults with chronic hepatitis C virus (HCV).
The marketing authorization is based on data from three Phase III trials, ION-1, ION-2 and ION-3, which evaluated eight, 12 or 24 weeks of treatment with Harvoni, with or without ribavirin, among nearly 2,000 genotype 1 HCV patients with compensated liver disease.
In January 2014, Harvoni was approved by the European Commission under the tradename Sovaldi.
The drug is recommended in treatment-naïve and treatment-experienced cirrhotic and non-cirrhotic genotype 1 and 4 patients with a treatment duration of 12 or 24 weeks depending on prior treatment history and cirrhosis status.
The company said that eight weeks of treatment with Harvoni may be considered in non-cirrhotic treatment-naïve genotype 1 patients.
Harvoni should be used in combination with ribavirin for 24 weeks in genotype 1 and 4 patients with decompensated cirrhosis, and genotype 3 patients with cirrhosis and/or prior treatment failure.
Queen Mary University professor of Hepatology Graham Foster said: "Genotype 1 patients living with hepatitis C in Europe and the physicians who treat them have been waiting for a treatment advance like this for decades.
"With Harvoni, we have the potential to transform the way we treat people living with the most prevalent form of hepatitis C in Europe.
"We can now expect very high SVR rates, and for many patients, we can eliminate the need for interferon injections and ribavirin and offer a cure in a once-daily tablet."
The European approval was also supported by preliminary data from the SOLAR-1 trial, which assessed difficult to treat patients with decompensated cirrhosis and patients who have undergone liver transplantation, as well as from the ERADICATE trial, which evaluated genotype 1 HCV patients co-infected with HIV.